MARÍA
ARESTIN MURUZABAL
Hospital de Cruces
Barakaldo, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Cruces (8)
2024
-
Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients
International Journal of Molecular Sciences, Vol. 25, Núm. 13
2021
2020
-
The urinary transcriptome as a source of biomarkers for prostate cancer
Cancers, Vol. 12, Núm. 2
2018
-
Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma
Scientific Reports, Vol. 8, Núm. 1
-
Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms
Journal of Molecular Diagnostics, Vol. 20, Núm. 1, pp. 34-45
2017
-
DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas
Pathology, Vol. 49, Núm. 7, pp. 731-739
2015
-
Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP
Experimental and Molecular Pathology, Vol. 99, Núm. 3, pp. 537-545
2014
-
Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes
Journal of Pathology, Vol. 232, Núm. 1, pp. 32-42